CSF2 and neuroblastoma: The results of our study compare also favorably with those of the initial randomized study of the combination of dinutuximab, a similar antibody to dinutuximab beta, with irinotecan and temozolomide plus GM-CSF in patients with relapsed/refractory neuroblastoma (23).